In 2025, the FDA approved 73 first-time generic drugs.  Here are the generics and their indication, in order of approval date: Note: The FDA’s information is current as of Dec. 18. 1. Phytonadione ...

Haemophilia is a rare inherited blood disorder characterised by poor blood clotting. It is typically caused by inherited gene changes affecting the production of clotting factors.The severity of ...

Joey Smiles has lived his whole life with the realization that if he gets a cut, the bleeding may not stop. The Pittston man was born with severe hemophilia, a blood clotting disorder, and takes an ...

A patient died after receiving Pfizer Inc.’s drug for hemophilia, marking another setback for the company in the treatment of blood disorders.The death occurred on Dec. 14 after the patient ...

Did you know that 1 in every 76 Americans is affected by a blood disorder? That means that a simple cut or routine surgery to many could become a serious problem to that person as they have the ...

Global Hematology Market OverviewThe global hematology market is projected to grow at a CAGR of approximately 3–5% through ...

Sanofi’s Qfitlia and Cablivi approved in China, expanding care for rare diseasesQfitlia, the first antithrombin-lowering therapy for hemophilia, ...

For men with hemophilia B, receipt of gene therapy comprising an infusion of etranacogene dezaparvovec results in sustained endogenous factor IX expression and low annualized bleeding rates over five ...

For men with hemophilia B, receipt of gene therapy comprising an infusion of etranacogene dezaparvovec results in sustained endogenous factor IX expression and low annualized bleeding rates over five ...

George Rodgers, III, MD, PhD, emphasized that antithrombin III’s expanded pediatric label provides "a sterile, plasma-derived product that will specifically correct the deficiency in a more safe ...

The U.S. Food and Drug Administration (FDA) announced on Friday that it is investigating a fatality linked to Adzynma, an FDA-approved therapy developed by Takeda (TAK) for a rare blood disorder known ...